Syngene Q4 PAT up 7 percent to Rs 148 crore
New Delhi: Contract manufacturing services firm Syngene International on Wednesday said its profit after tax (PAT), before accounting for exceptional items, increased by 7 per cent to Rs 148 crore in the fourth quarter ended March 31.The company had reported a PAT of Rs 138 crore in the January-March period of 2020-21.Revenue from operations rose to Rs 758 crore during the quarter against Rs...
New Delhi: Contract manufacturing services firm Syngene International on Wednesday said its profit after tax (PAT), before accounting for exceptional items, increased by 7 per cent to Rs 148 crore in the fourth quarter ended March 31.
The company had reported a PAT of Rs 138 crore in the January-March period of 2020-21.
For the year ended March 31, 2022, the company posted a PAT of Rs 421 crore compared to Rs 382 crore in FY21.
"Reflecting on the pandemic period, we created more than 1,000 new jobs in the last two years and gained more than 100 new clients in the last year. We also extended and expanded our long-term partnership with Amgen Inc and continued to invest in new capacity and technology to underpin future growth," Syngene International MD and CEO Jonathan Hunt noted.
Read also: Syngene announces expansion of biomanufacturing capacity
Looking ahead, the company expects growing demand for research, development and manufacturing services around the world and Syngene is well-positioned to take advantage of these new opportunities, he added.
On the outlook for FY23, the company said overall revenues from operations are expected to grow in the mid-teens.
The company said its board has recommended a final dividend of Re 1 per share of Rs 10 each for the financial year March 31, 2022.
Read also: Syngene International extends collaboration with Amgen
Syngene is an integrated research, development and manufacturing organisation providing scientific services – from early discovery to commercial supply. The company offers services in a wide range of industrial sectors, including pharmaceutical, biotechnology, nutrition, animal health, consumer goods and speciality chemical companies.
Read also: Syngene appoints Alex Del Priore, Dr Alan Collis as new senior leaders in US
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd